Список литературы

23. Macklon N.S., Fauser B.C. Impact of ovarian hyperstimulation on the luteal phase. J. Reprod. Fertil. Suppl. 2000; 55: 101–108.

24. IVF Worldwide. An updated survey: the use of progesterone for luteal phase support. Доступно по ссылке http://www.ivf-worldwide.com/survey/an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles/results-an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles.html.

25. ESHRE Early Pregnancy Guideline Development Group. Recurrent pregnancy loss: guideline of the European Society of Human Reproduction and Embryology. 2017.

26. Abbott Laboratories. Company Core Data Sheet. Dydrogesterone. 5 июля 2017 г.

27. Besins Healthcare (UK) Ltd. Utrogestan 100 mg oral capsules. Summary of Product Characteristics UK. 14 июля 2017 г.

28. Besins Healthcare (UK Ltd. Utrogestan vaginal 200 mg capsules. Summary of Product Characteristics UK. 29 June 2017.

29. Linden M., Buckingham K., Farquhar C. et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015: CD009154.

30. Czajkowski K., Sienko J., Mogilinski M., Bros M., Szczecina R., Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil. Steril. 2007; 87: 613–618. doi: 10.1016/j.fertnstert.2006.07.1506.

31. Guerra J.A., López-Muñoz F., Álamo C. Progestins in combined contraceptives. J Exp. Clin. Med. 2013; 5: 51–55. doi: 10.1016/j. jecm.2013.02.007.

32. Davar R., Farid Mojtahedi M., Miraj S. Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT. Iran J Reprod Med. 2015; 13(8): 483: 488–710.

33. Yanushpolsky E.H. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015; 33(2): 118–127.

34. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019–1027.

35. Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012; 25(2): 139–145.

36. Makhmudova G.M., Nazhmutdinova D.K., Gafarova D.K., Lukmanova Y.D. Efficacy of duphaston treatment in women with endometriosis after reconstructive surgery. Akush. Ginekol. (Sofiia). 2003; 42: 42–46.

37. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol. Endocrinol. 2016; 32: 97–106. doi: 10.3109/09513590.2015.1121982. Moszkowski E., Woodruff J.D., Jones G.E. The inadequate luteal phase. Am. J. Obstet. Gynecol. 1962; 83: 363–372.

38. Rižner T.L., Brožič P., Doucette C. et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607–615.

39. Schindler A.E., Campagnoli C., Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1–2): 171–180.

40. Stanczyk F.Z., Hapgood J.P., Winer S. et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34(2): 171–208; doi: 10.1210/er.2012-1008.

41. Abbott B.V. 8 June 2017. Duphaston 10, film-coated tablets 10 mg Summary of Product Characteristics.

42. Arvidsson C., Hellborg M., Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 123: 87–91. doi: 10.1016/j.ejogrb.2005.02.019.

43. Bingham J.S. Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br. J. Vener. Dis. 1984; 60: 175–177.

44. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J. Steroid Biochem. Mol. Biol. 2005; 97: 416–420. doi: 10.1016/j.jsbmb.2005.08.012.

45. Patki A., Pawar V.C. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007; 23(Suppl 1): 68–72.

46. Paulson R.J., Collins M.G., Yankov V.I. Progesterone Pharmacokinetics and Pharmacodynamics With 3 Dosages and 2 Regimens of an Effervescent Micronized Progesterone Vaginal Insert. J Clin Endocrinol Metab. 2014; 99(11): 4241–4249.

47. Tavaniotou A., Smitz J., Bourgain C., Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000; 6(2): 139–148.

48. Reerink E.H., Scholer H.F., Westerhof P., Querido A., Kassenaar A.A., Diczfalusy E., Tillinger K.C. A new class of hormonally active steroids. Nature. 1960; 186: 168–169.

49. Zafardoust S., Jeddi-Tehrani M., Mehdi Akhondi M. et al. Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Outcome of ICSI-ET Cycles in Women with Previous History of IVF/ICSI Failure: A Randomized Controlled Trial. J Reprod Infertil. 2015; 16(2): 96–101.

50. Tomic V., Tomic J., Klaic D.Z., Kasum M., Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 186: 49–53. doi: 10.1016/j.ejogrb.2014.11.002.

51. Zargar M.N.S., Ejtahed M. Comparison the effectiveness of oral dydrogesterone, vaginal progesterone suppository and progesterone ampule for luteal phase support on pregnancy rate during ART cycles. Int. J. Pharma. Res. Allied Sci. 2016; 5: 229–236.

52. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010; 340: c221. Epub 2010/02/09. https://doi.org/10.1136/bmj.c221PMID: 20139215.

53. Abdel-Razik M., El-Berry S., Mostafa A. The effects of nitric oxide donors on uterine artery and sub-endometrial blood flow in patients with unexplained recurrent abortion. J Reprod Infertil. 2014; 15: 142–146

54. Kaňová N., Bičiková M. Hyperandrogenic states in pregnancy. Physiol Res. 2011; 60(2): 243–252.

55. Wang M.H., Baskin L.S. Endocrine disruptors, genital development, and hypospadias. J Androl. 2008; 29(5): 499–505.

56. Nordic Pharma Limited. Gestone 50 mg/2 ml. Summary of Product Characteristics UK. 3 августа 2007 г.

57. Marcyrl Pharmaceutical Industries. Prontogest Progesterone 100 mg Ampoules. Patient Leaflet.

58. Paulson R.J., Collins M.G., Yankov V.I. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J. Clin. Endocrinol. Metab. 2014; 99: 4241–4249. doi: 10.1210/jc.2013-3937.

59. Ganesh A., Chakravorty N., Mukherjee R. et al. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 2011; 95(6): 1961–1965.

60. Pang Y., Dong J., Thomas P. Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-α. Am. J. Physiol. Endocrinol. Metab. 2015; 308: E899–E911. doi: 10.1152/ajpendo.00527.2014.

61. Simoncini T., Caruso A., Giretti M.S., Scorticati C., Fu X.D., Garibaldi S., Baldacci C., Mannella P., Fornari L., Genazzani A.R. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil. Steril. 2006; 86: 1235–1242. doi: 10.1016/j. fertnstert.2006.05.018.

62. Fatemi H.M., Bourgain C., Donoso P. et al. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept. Hum Reprod. 2007; 22(5): 1260–1263.

63. Saharkhiz N., Zamaniyan M., Salehpour S., Zadehmodarres S, Hoseini S., Cheraghi L. et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol. 2016; 32(3): 213–7. https://doi.org/10.3109/09513590.2015. 1110136. PMID: 26486011.

64. Salehpour S., Tamimi M., Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): a randomized clinical trial. Iran J. Reprod. Med. 2013; 11: 913–918.

65. Rashidi B.H., Ghazizadeh M., Tehrani Nejad E.S., Bagheri M., Gorginzadeh M. Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: A pilot randomized controlled trial. Asian Pacific Journal of Reproduction. 2016; 5: 490–494. doi: 10.1016/j. apjr.2016.10.002.

66. Zarei A., Sohail P., Parsanezhad M.E., Alborzi S., Samsami A., Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch. Gynecol. Obstet. 2017; 295: 239–246. doi: 10.1007/s00404-016-4217-4.

67. Сarp H.J.A. Progesterons in luteal support. Hormone Molecular Biology and Clinical Investigation. 2020. URL: http:/doi.org/10.1515/hmbci-2019-0067.

68. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009; 65(Suppl 1): S3–S11.

69. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W. et al. Classification and pharmacology of progestins. Maturitas. 2003; 46: S7–S16. Epub 2003/12/13. https://doi.org/10.1016/j.maturitas.2003.09.014. PMID: 14670641.

70. Chambers G.M., Hoang V.P., Zhu R., Illingworth P.J. A reduction in public funding for fertility treatment — an econometric analysis of access to treatment and savings to government. BMC Health Serv. Res. 2012; 12: 142. doi: 10.1186/1472-6963-12-142.

71. Colombo D., Ferraboschi P., Prestileo P., Toma L. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J. Steroid Biochem. Mol. Biol. 2006; 98: 56–62. doi: 10.1016/j.jsbmb.2005.07.009.

72. Paulson R.J., Collins M.G., Yankov V.I. Progesterone Pharmacokinetics and Pharmacodynamics With 3 Dosages and 2 Regimens of an Effervescent Micronized Progesterone Vaginal Insert. J Clin Endocrinol Metab. 2014; 99(11): 4241–4249.